A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

324

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

December 30, 2024

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG

SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316

"Drug: SHR-A1811 \& Pyrotinib~SHR-A1811： intravenous Pyrotinib：oral~Drug: SHR-A1811 \& SHR-1316~SHR-A1811： intravenous SHR-1316： intravenous"

Trial Locations (2)

RECRUITING

Shanghai Chest hospital, Shanghai

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY